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Abstract The understanding of cellular processes and their
pathophysiological alterations requires comprehensive data
on the abundance, distribution, modification, and interac-
tion of all cellular components. On the one hand, artificially
introduced fluorescent fusion proteins provide information
about their distribution and dynamics in living cells but not
about endogenous factors. On the other hand, antibodies
can detect endogenous proteins, posttranslational modifica-
tions, and other cellular components but mostly in fixed and
permeabilized cells. Here we highlight a new technology
based on the antigen-binding domain of heavy-chain
antibodies (VHH) from Camelidae. These extremely stable
VHH domains can be produced in bacteria, coupled to
matrices, and used for affinity purification and proteome
studies. Alternatively, these VHH domains can be fused
with fluorescent proteins and expressed in living cells.
These fluorescent antigen-binding proteins called “chromo-
bodies” can be used to detect and trace proteins and other
cellular components in vivo. Chromobodies can, in princi-
ple, detect any antigenic structure, including posttransla-
tional modifications, and thereby dramatically expand the
quality and quantity of information that can be gathered in
high-content analysis. Depending on the epitope chosen,
chromobodies can also be used to modulate protein
function in living cells.
Keywords Antibodies.Nanobodies.High-content
analysis.Proteomics.Green fluorescent protein.
Fluorescent proteins
Introduction/background
A multitude of biochemical and cell-based assays have
been developed to study proteins and cellular processes.
The discovery of the green fluorescent protein (GFP) [1, 2]
as well as the subsequent isolation and engineering of
fluorescent proteins with distinct and optimized spectral
properties have revolutionized cell biology [3, 4]. Fluores-
cent proteins can be used as reporters of gene expression or
genetically fused with proteins of interest to study their
localization and dynamics in living cells. Fluorescent
proteins have been used to study cellular processes ranging
from DNA replication and cell cycle progression to DNA
methylation and repair [5–9].
This approach is, however, limited to the visualization of
artificially introduced fluorescent fusion proteins, whereas
the endogenous proteins of interest remain invisible.
Importantly, artificial fusion proteins may considerably
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expression level, activity, and localization [10, 11]. Finally,
fluorescent fusions are limited to proteins and do not
provide information about nonprotein components and
posttranslational modifications.
In contrast, antibodies can detect practically any
molecular component and cellular structure and are
therefore powerful tools in biomedical research. Conven-
tional antibodies consist of two identical heavy (H) and
two light (L) chains, each comprising a variable domain at
the N-terminus (abbreviated as VH and VL, respectively).
Antibodies specifically recognize and bind their target
molecules (antigens) via complementarity-determining
regions located in the variable domains of the heavy and
light chains. Generated by a highly sophisticated immune
response system, antibodies are naturally secreted or are
located at the cell surface as an essential part of the
defense strategy against pathogens. However, their appli-
cation within cells is limited by impaired disulfide bond
formation in the reducing environment of the cytoplasm,
inefficient assembly of the epitope-recognizing parts of the
variable light and heavy chains, and difficult subcellular
targeting [12, 13]. To make cellular target structures
accessible for antibodies, cells have to be fixed and
permeabilized. Therefore, antibodies only provide snap-
shots of the distribution of the antigen, and no information
about the dynamics or mobility can be obtained.
Camelid antibodies
Based on conventional antibodies (IgG, 150 kDa), a
number of recombinant antibody formats such as monova-
lent antibody fragments (Fab, 50 kDa) and single-chain
variable fragments (scFv, 25 kDa) have been developed
during the last decade, increasing the stability and the
accessibility of antigen-binding molecules. However, as
these antibody derivatives are composed of heavy- and
light-chain domains, their application in living cells is still
hampered by inefficient folding and disulfide bond forma-
tion. So far, only in a few cases have intracellular antibody
derivates been successfully used for protein analysis in vivo
[14–17].
One alternative to conventional antibodies is provided by
nature itself. The humoral immune response of camels,
dromedaries, and llamas includes a unique type of anti-
bodies devoid of light chains, the so-called heavy-chain
antibodies [18]. They recognize and bind their antigen via a
single variable domain, the VHH (variable heavy chain of a
heavy-chain antibody). With a molecular mass of approx-
imately 13 kDa and a size in the range of approximately
2 nm×4 nm, VHHs represent the smallest intact naturally
occurring antigen-binding fragments and are therefore often
called “nanobodies” [19, 20]. Nanobodies provide a series
of advantages in comparison with other antibody fragments
such as Fab and scFv. First, only a single domain has to be
cloned and expressed to generate an intact antigen-binding
fragment. Nanobodies are in vivo affinity matured entities
that do not need in vitro affinity maturation steps as are
often required with binders from naive or synthetic
libraries. Second, specific nanobodies can be easily selected
via phage display. Third, owing to their structure, nano-
bodies are extremely stable and soluble and they can be
efficiently produced in heterologous expression systems
including genetic fusions with fluorescent proteins [21, 22].
Last but not least, the antigen binding affinities of nano-
bodies in the nanomolar range are similar to those of scFvs
[23, 24].
Chromobodies as molecular probes in living
cells: closing the gap between fluorescent probes
and end-point assays
The robustness and structural simplicity of nanobodies offer
a wide field of new applications in molecular and cellular
diagnostics. Most intriguingly and in contrast to conven-
tional antibodies, nanobodies that are functional in living
cells can be identified and selected from large VHH
libraries.
On the basis of this unique characteristic, we established
a new class of cellular biomarkers by genetically fusing
nanobodies with fluorescent proteins for visualization of
antigens in living mammalian cells. Owing to their chimeric
structure, these recombinant derivatives were termed
“chromobodies” (Fig. 1a). In a proof-of-concept study,
chromobodies were introduced as promising, novel tools in
cell biology research [25]. They were shown to detect
antigens in chromatin and replication complexes as well as
the cytoskeleton and allowed the visualization of dynamic
changes during the cell cycle in real time, proving their
applicability in different subcellular compartments. In
addition a chromobody against the nuclear lamina (lamin
chromobody) was generated and tested [25]. Despite
transient binding, this lamin chromobody was sufficient to
detect the nuclear lamina. Moreover, the transient binding
mode seemed to minimize functional interference and
allowed cells to pass through mitosis (Fig. 1b). Since the
binding strength of chromobodies can be genetically
engineered, they can be fine-tuned for optimal detection
and minimal biological interference.
Since chromobodies allow for targeting and tracing of a
wide range of endogenous structures, including posttrans-
lational modifications and nonprotein components, in their
dynamic, cellular environment they should be capable of
closing the analytical gap between live-cell-applicable,
3204 K. Schmidthals et al.fluorescent fusion proteins, and antibody-based detection
assays on fixed cells (end-point assays).
Chromobodies in high-content analysis
In the early stage of pharmaceutical drug development, high-
contentanalysis(HCA)isanimportanttechnology,aimingfor
maximal readout of cellular parameters in terms of both
quality and quantity. This way, compound libraries are
screened and analyzed for desired effects and/or possible side
effects at the cellular level. Based on high-throughput
microscopy with automated image acquisition and computa-
tional pattern recognition in multiwell formats, HCA facili-
tates the simultaneous investigation of multiple cellular
biomarkers in a statistically secured manner. However, HCA
is limited by the availability of reliable biomarkers. To
exemplify that chromobodies can complement and extend
existing diagnostic approaches, we set up a first cellular assay
for real-time monitoring of apoptosis in HeLa cells. We
generated a cell line stably expressing the lamin chromobody
to visualize the nuclear lamina. In this case, the cellular
parameter of interest is the integrity of the nuclear lamina.
Upon addition of apoptosis-inducing agents (such as staur-
osporine), fragmentation of the nuclear lamina can be
monitored in real time. Using automated image acquisition
Fig. 1 The chromobody tech-
nology. a Chromobodies. b De-
tection of the nuclear lamina
with lamin chromobody in liv-
ing cells. Confocal images of
HeLa cells coexpressing lamin
chromobody (green) and red
fluorescent histone H2B as a
mitosis marker. Cells in pro-
phase, G2 phase, and anaphase
are shown (from left to right),
the latter displaying breakdown
of the nuclear lamina, concomi-
tant with chromosome separa-
tion (right). The scale bar
represents 10 µm
Fig. 2 Apoptosis assay with a lamin chromobody expressing cell line.
a Time lapse imaging of untreated cells (upper row) and after addition
of 5 μM staurosporine (STS). The nuclear lamina is visualized with a
lamin chromobody (green). Selected images before and after
(645 min) addition of STS are shown. b Quantitative evaluation with
automated image acquisition and computational pattern recognition.
Morphological changes of the lamina (fragmentation and vesicle
formation) were monitored in 15-min intervals. The percentage of
apoptotic cells after treatment with increasing concentrations of STS
(0–5 µM) over a time period of 20 h is shown
Novel antibody derivatives for proteome and high-content analysis 3205and computational pattern recognition, we detected an
increasing percentage of apoptotic cells, with higher staur-
osporine concentrations (Fig. 2).
Chromobodies may be used not only to track and
visualize cellular components as described for the nuclear
lamina, but also for pharmaceutical target validation.
Chromobodies can, in principle, be generated against all
surface epitopes to specifically block regulatory or catalytic
domains, which resembles more closely the block of
pharmaceutical, small molecules than presently used
knockdown/knockout studies. Therefore, chromobodies
enable new functional studies and may provide valuable
information concerning target suitability at a very early
stage of drug development.
Modulation of protein shape and function
with nanobodies in living cells
Complex cellular processes are mostly regulated through
synthesis, modification, and degradation of proteins.
Besides these intensively investigated mechanisms, cor-
rect protein folding is essential for cellular processes.
This is emphasized by the fact that severe diseases such
as Creutzfeldt–Jakob disease and mad cow disease (BSE)
are directly linked to protein misfolding. In both cases,
changes in protein folding turn naturally harmless
proteins into lethal, infectious particles (prions) [26].
Interestingly, several nanobodies were described that
directly influence enzymatic function, protein folding,
Fig. 3 Modulation of protein properties with nanobodies. a Structural
surface representation of green fluorescent protein (GFP)( green;
Protein Data Bank file 1EMB [40]), GFP bound by Minimizer
nanobody (red; Protein Data Bank file 3G9A [31]), and GFP bound
by Enhancer nanobody (red; Protein Data Bank file 3K1K [31]). Both
nanobodies induce subtle conformational changes in the chemical
environment of the GFP chromophore, thereby altering its fluorescent
properties towards decreased fluorescence intensity (Minimizer) or
enhanced fluorescence intensity (Enhancer). b Fluorescence modula-
tion in living cells. Exemplary HeLa cells are shown, expressing
nuclear localized GFP, GFP and Minimizer (red), and GFP and
Enhancer (red). The scale bars represent 10 µm
Fig. 4 Nanotraps for biochemical applications. a VHH-based nano-
traps. b Example of the use of a GFP-specific nanotrap immunopre-
cipitation of GFP–profilerating cell nuclear antigen (PCNA)
(approximately 60 kDa) from a crude cell lysate of GFP-PCNA
expressing HEK 293T cells. Input (I) and bound (B) fractions were
subjected to sodium dodecyl sulfate polyacrylamide gel electrophore-
sis followed by Coomassie staining. The GFP-Trap facilitates specific
purification of GFP fusion proteins and their interaction partners
3206 K. Schmidthals et al.and protein aggregation or detect specific protein con-
firmations in vitro [27–30].
In a first pilot study we recently demonstrated that
nanobodies can be utilized to manipulate and modulate the
conformational state of proteins in living cells: Upon binding
to GFP, two oppositely acting nanobodies cause functional
three-dimensional changes resulting in decreased or increased
fluorescence intensities of GFP in living cells (Fig. 3)[ 31].
We then exploited this effect to monitor shuttling of a
transcription factor from the cytoplasm to the nucleus,
depending on fluorescence changes that were induced upon
nanobody binding. Again, these findings underline that
nanobodies and chromobodies offer huge versatility and that
many new applications can be expected.
Nanobodies for biochemical studies
Besides their unique applicability in living cells, nano-
bodies also proved to be valuable tools for the biochemical
purification and analysis of cellular components and
complexes. In contrast to conventional antibodies, nano-
bodies provide a number of advantages. First, they can be
produced bacterially in unlimited amounts and reproducible
quality, offering experimental reliability. Second, nano-
bodies are characterized by high robustness regarding heat
as well as extreme salt and pH conditions [24, 32, 33].
Third, although comprising a small binding interface, the
binding affinity of nanobodies is sufficiently high, and
owing to the small surface fewer unspecific interactions
seem to occur [33]. Furthermore, nanobodies can easily be
coupled to beads, matrices, or even microarray chip
surfaces, to generate antigen-specific nanotraps. Since
nanotraps are covalently coupled single-chain peptides,
elution of heavy and light chains as with conventional
antibodies is prevented, an advantage for subsequent
biochemical analysis.
On the basis of these favorable characteristics, we
recently established a highly efficient system for the
purification of GFP fusion proteins and their associated
interaction partners from crude biological samples (Fig. 4,
GFP-Trap) [33]. This new tool is now being widely used
for protein–protein interaction studies, enzymatic assays,
chromatin immunoprecipitations, and high-throughput pro-
teomics [34–37].
Outlook
Recombinant antibody technologies as established during the
last decade enable a wide variety of novel applications for
biomedical research especially for molecular and cellular
biology. In particular, single domain antibody derivates such
as the nanobodies, chromobodies, and nanotraps described
here have several decisive advantages as they can be selected
from recombinant libraries [38, 39]. Nanobodies can be
produced in prokaryotes and eukaryotes and used for new
functional studies in vitro and in vivo. Recent proof-of-
principle studies demonstrated that the chromobody technol-
ogy is applicable for real-time HCA, that nanobodies can be
used to modulate protein properties in living cells, and that
nanotraps represent a new class of highly efficient tools for
biochemical and proteomic research. After these first
demonstrations of the versatility of these new antibody
formats, a plethora of new in vivo and in vitro applications
are to be expected in the next years.
These developments will likely include chromobodies as
biomarkers for HCA and live cell analysis providing an
optical readout of essential cellular processes such as signal
transduction, cell cycle progression, epigenetic regulation,
and posttranslational modifications. At present, the rate-
limiting factor is the still-limited availability of specific
nanobodies as the best binders are still derived in a time-
consuming procedure from in vivo matured heavy-chain
antibodies. Thus the development of better selection and in
vitro maturation procedures for the isolation and engineer-
ing of highly specific binders is of utmost importance.
Acknowledgements This work was supported by the GO-Bio
Program of the BMBF and the Deutsche Forschungsgemeinschaft
(DFG).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Tsien RY (1998) Annu Rev Biochem 67:509–544
2. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994)
Science 263:802–805
3. Heim R, Tsien RY (1996) Curr Biol 6:178–182
4. Shaner NC, Steinbach PA, Tsien RY (2005) Nat Methods 2:905–909
5. Leonhardt H, Rahn HP, Weinzierl P, Sporbert A, Cremer T et al
(2000) J Cell Biol 149:271–280
6. Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB et
al (2005) Nat Methods 2:751–756
7. Easwaran HP, Leonhardt H, Cardoso MC (2005) Cell Cycle
4:453–455
8. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt
H (2005) Proc Natl Acad Sci USA 102:8905–8909
9. Spada F, Haemmer A, Kuch D, Rothbauer U, Schermelleh L et al
(2007) J Cell Biol 176:565–571
10. Chalfie M, Kain S (2005) Green fluorescent protein: properties,
applications and protocols. Wiley, Totowa
11. Leonhardt H, Rahn HP, Cardoso MC (1998) J Cell Biochem
Suppl 30–31:243–249
12. Biocca S, Neuberger MS, Cattaneo A (1990) EMBO J 9:101–108
13. Cattaneo A, Biocca S (1999) Trends Biotechnol 17:115–121
14. Biocca S, Pierandrei-Amaldi P, Cattaneo A (1993) Biochem
Biophys Res Commun 197:422–427
Novel antibody derivatives for proteome and high-content analysis 320715. Cardinale A, Lener M, Messina S, Cattaneo A, Biocca S (1998)
FEBS Lett 439:197–202
16. Kontermann RE (2004) Methods 34:163–170
17. Marasco WA, Chen S, Richardson JH, Ramstedt U, Jones SD
(1998) Hum Gene Ther 9:1627–1642
18. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G,
Hamers C et al (1993) Nature 363:446–448
19. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R
(1994) Protein Eng 7:1129–1135
20. Muyldermans S (2001) J Biotechnol 74:277–302
21. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P,
De Genst E et al (2009) Vet Immunol Immunopathol 128:178–
183
22. Olichon A, Surrey T (2007) J Biol Chem 282:36314–36320
23. Sheriff S, Constantine KL (1996) Nat Struct Biol 3:733–736
24. van der Linden RH, Frenken LG, de Geus B, Harmsen MM,
Ruuls RC et al (1999) Biochim Biophys Acta 1431:37–46
25. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L et al
(2006) Nat Methods 3:887–889
26. Prusiner SB (2001) N Engl J Med 344:1516–1526
27. Lauwereys M, Arbabi GM, Desmyter A, Kinne J, Holzer W et al
(1998) EMBO J 17:3512–3520
28. Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D et al
(2003) Nature 424:783–788
29. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F (2009)
Mol Immunol 46:695–704
30. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C et al
(2007) Proc Natl Acad Sci USA 104:19232–19237
31. Kirchhofer A, Helma J, Schmidthals K, Frauer C, Cui S et al
(2010) Nat Struct Mol Biol 17:133–138
32. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muylder-
mans S (1997) FEBS Lett 414:521–526
33. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso
MC et al (2008) Mol Cell Proteomics 7:282–289
34. Trinkle-Mulcahy L, Boulon S, Lam YW, Urcia R, Boisvert FM et
al (2008) J Cell Biol 183:223–239
35. Rogowski K, Juge F, van Dijk J, Wloga D, Strub JM et al (2009)
Cell 137:1076–1087
36. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H et al (2009)
Science 325:90–93
37. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM et al
(2009) Nature 462:935–939
38. Tanha J, Xu P, Chen Z, Ni F, Kaplan H et al (2001) J Biol Chem
276:24774–24780
39. Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M et al
(2009) Protein Eng Des Sel 22:273–280
40. Brejc K, Sixma TK, Kitts PA, Kain SR, Tsien RYet al (1997) Proc
Natl Acad Sci USA 94:2306–2311
3208 K. Schmidthals et al.